EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tailored Levofloxacin Incorporated Extracellular Matrix Nanoparticles for Pulmonary Infections

Raahi Patel iD, Ignacio Moyano, Masahiro Sakagami iD, Jason D Kang, Phillip B Hylemon, Judith A Voynow iD, Rebecca L Heise iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26157453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Raahi Patel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA 23219, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Extracellular Matrix, Levofloxacin, Nanoparticles. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institute of Health, Cystic Fibrosis Foundation Student Traineeship Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis produces viscous mucus in the lung that increases bacterial invasion, causing persistent infections and subsequent inflammation. Pseudomonas aeruginosa and Staphylococcus aureus are two of the most common infections in cystic fibrosis patients that are resistant to antibiotics. One antibiotic approved to treat these infections is levofloxacin (LVX), which functions to inhibit bacterial replication but can be further developed into tailorable particles. Nanoparticles are an emerging inhaled therapy due to enhanced targeting and delivery. The extracellular matrix (ECM) has been shown to possess pro-regenerative and non-toxic properties in vitro, making it a promising delivery agent. The combination of LVX and ECM formed into nanoparticles may overcome barriers to lung delivery to effectively treat cystic fibrosis bacterial infections. Our goal is to advance CF care by providing a combined treatment option that has the potential to address both bacterial infections and lung damage. Two hybrid formulations of a 10:1 and 1:1 ratio of LVX to ECM have shown neutral surface charges and an average size of ~525 nm and ~300 nm, respectively. The neutral charge and size of the particles may suggest their ability to attract toward and penetrate through the mucus barrier in order to target the bacteria. The NPs have also been shown to slow the drug dissolution, are non-toxic to human airway epithelial cells, and are effective in inhibiting Pseudomonas aeruginosa and Staphylococcus aureus. LVX-ECM NPs may be an effective treatment for pulmonary CF bacterial treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsExtracellular MatrixLevofloxacinNanoparticlesPseudomonas InfectionsAnimalsHumansCystic FibrosisPseudomonas aeruginosaStaphylococcal InfectionsStaphylococcus aureus

Stichwörter der Autor:innen

cystic fibrosisextracellular matrixlevofloxacinmucus barriernanoparticlespulmonary delivery

Substanzen

Anti-Bacterial AgentsLevofloxacin

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA 23219, USA.
  • Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23219, USA.
  • Stravitz-Sanyal Institute for Liver Disease & Metabolic Health, School of Medicine, Virginia Commonwealth University, Richmond, VA 23219, USA.
  • Department of Microbiology and Immunology, School of Medicine, Virginia Commonwealth University, Richmond, VA 23219, USA.
  • Division of Pediatric Pulmonology, Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, VA 23298, USA.

ORCID-Profile: Raahi Patel, Masahiro Sakagami, Judith A Voynow, Rebecca L Heise

Förderung

  • NIH HHS
  • National Institute of Health
  • Cystic Fibrosis Foundation Student Traineeship Award

Zitieren

APA

Patel, R., Moyano, I., Sakagami, M., Kang, J. D., Hylemon, P. B., Voynow, J. A., & Heise, R. L. (2025). Tailored Levofloxacin Incorporated Extracellular Matrix Nanoparticles for Pulmonary Infections. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157453

Vancouver

Patel R, Moyano I, Sakagami M, Kang JD, Hylemon PB, Voynow JA, et al. Tailored Levofloxacin Incorporated Extracellular Matrix Nanoparticles for Pulmonary Infections. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157453

BibTeX
@article{Patel2025,
  author = {Patel, Raahi and Moyano, Ignacio and Sakagami, Masahiro and Kang, Jason D and Hylemon, Phillip B and Voynow, Judith A and Heise, Rebecca L},
  title = {Tailored Levofloxacin Incorporated Extracellular Matrix Nanoparticles for Pulmonary Infections},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26157453}
}
Kostenlos starten →